AT 177
Alternative Names: AT-177Latest Information Update: 28 Mar 2023
At a glance
- Originator Azora Therapeutics
- Class Anti-inflammatories; Indoles; Small molecules
- Mechanism of Action Aryl hydrocarbon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ulcerative colitis
- Research Unspecified
Most Recent Events
- 28 Mar 2023 Early research in Unspecified in USA (unspecified route) (Azora Therapeutics pipeline, March 2023)
- 28 Mar 2023 Preclinical trials in Ulcerative colitis in USA (unspecified route) (Azora Therapeutics pipeline, March 2023)
- 05 Aug 2021 Azora Therapeutics has patents pending for indigo derivatives in multiple countries worldwide, including USA, before August 2021